touchPODCAST

touchCASES for touchNEUROLOGY, touchCARDIO, touchENDOCRINOLOGY and touchRESPIRATORY Listen to two experts as they discuss three cases illustrating the heterogeneous, multisystem nature of late-onset Pompe disease (LOPD). They examine key decision points from recognizing early clinical clues and confirming diagnosis to optimizing enzyme replacement therapy (ERT), monitoring progression and coordinating multidisciplinary, patient-centred care.  The experts: Prof. John Vissing, University of Copenhagen, Copenhagen, Denmark Prof. Pascal Laforêt, Versailles-Saint Quentin University, Versailles, France  This activity is for HCPs outside of the USA. This activity is supported by an independent educational grant from Amicus Therapeutics UK LTD. touchIME is an EBAC® accredited provider. For further information visit our websites:  touchNEUROLOGY -  https://touchneurologyime.org/diagnosis-monitoring-management-lopd/ touchCARDIO - https://touchcardioime.org/diagnosis-monitoring-management-lopd/ touchENDOCRINOLOGY - https://touchendocrinologyime.org/diagnosis-monitoring-management-lopd/ touchRESPIRATORY - https://touchrespiratoryime.org/diagnosis-monitoring-management-lopd/  

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice.   Overview Data reviews with Dr Popat Expert panel discussions with Dr Popat, Dr Rodríguez-Otero and Dr Mina on the themes below Clinical themes Approved BCMA-directed therapeutic approaches  Practical application of BCMA-directed therapies Future of treating RRMM: Emerging BCMA-directed therapies and combinations The internationally renowned multiple myeloma expert faculty Dr Rakesh Popat: London, UK Dr Paula Rodríguez-Otero: Pamplona, Spain Dr Roberto Mina: Atlanta, GA, USA This touchPODCAST is for HCPs outside of the USA.  This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France   Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA   Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Paul Hofman, University Côte d’Azur, Nice, France.     This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/  

touchEXPERT FOCUS for touchONCOLOGY Listen to insights from Dr Kathleen Moore on the pathophysiology and molecular features of low-grade serous ovarian cancer (LGSOC) and how it differs from other ovarian cancers. She also discusses evidence-based treatment options and sequencing, as well as practical considerations relating to administration and side-effect management. The expert: Dr Kathleen Moore, OH Health Stephenson Cancer Center, Oklahoma City, OK, USA This touchPODCAST is for HCPs in the USA only. This activity is funded by an independent medical education grant from Verastem, Inc. The activity is jointly provided by Partners for Advancing Clinical Education and touchIME. For further information visit our website: www.touchONCOLOGY.com

touchIN CONVERSATION for touchHAEMATOLOGY The presence of anaemia and/or thrombocytopenia complicates the management of patients with myelofibrosis (MF). Listen to expert haematologists consider the burden of cytopenias in patients with MF and discuss strategies to reduce transfusion dependence, improve splenomegaly and personalize treatment with JAK inhibitors. The experts Prof. Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK Dr Laura Fox, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain This touchPODCAST is for HCPs outside of the USA. This activity is supported by an independent medical education grant from GSK. This activity is provided by touchIME in collaboration with our Education Partner Haematology Nurses & Healthcare Professionals Group (HNHCP). touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com

touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY Listen to a series of short interviews with three leading experts who provide their insights into early-line management of chronic myeloid leukaemia and the impact on quality of life. The experts: Dr Delphine Rea, Hôpital Saint-Louis, Paris, France  Prof. Andreas Hochhaus, Jena University Hospital, Jena, Germany Prof. Etab Atallah, Medical College of Wisconsin, Milwaukee, WI, USA This activity is for healthcare professionals outside of the USA and UK. This independent medical education is supported by Novartis and is provided by touchIME. For further information visit our website: www.touchHAEMATOLOGY.com or www.touchONCOLOGY.com

touchTALKS for touchONCOLOGY Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making. The expert Dr Christine Bestvina, University of Chicago, Chicago, IL, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: www.touchONCOLOGY.com

touchEXPERT FOCUS for touchONCOLOGY Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA.  The experts Prof. Thomas Seufferlein, Ulm University, Ulm, Germany Dr Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust, Oxford, UK Prof. Florian Lordick, University of Leipzig, Leipzig, Germany Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium This touchPODCAST is for HCPs outside of the UK This activity is supported by an independent educational grant from Jazz Pharmaceuticals.  Jointly provided by Partners for Advancing Clinical Education and touchIME.  touchIME is an EBAC® accredited provider.  For further information visit our website:  www.touchONCOLOGY.com

touchPANEL DISCUSSION for touchONCOLOGY and touchENDOCRINOLOGY Listen to a panel of leading experts discuss the optimal management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs), with a focus on peptide receptor radionuclide therapy (PRRT). The faculty provide their insights on the current state of the art, the evolving role of PRRT in GEP-NET treatment, and recent data with existing and emerging PRRT agents. The faculty will also consider future developments in this field, including personalized approaches to PRRT, and how they might impact clinical care. The experts: Prof. Thorvardur Halfdanarson, Mayo Clinic Rochester, MN, USA Prof. Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Madrid, Spain Prof. Nicola Fazio, European Institute of Oncology, Milan, Italy This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from ITM Isotope Technologies Munich SE. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchONCOLOGY.com and www.touchENDOCRINOLOGY.com

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets In this module, Professor Pasi Jänne and Dr Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/  

touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen to a series of interviews with two medical retina specialists and a biomarker expert who will provide their insights into the pathophysiology of diabetic macular oedema (DMO), including the inflammatory mechanisms of disease and how they may impact treatment. The faculty will also consider the clinical utility of optical coherence tomography (OCT) imaging biomarkers and emerging evidence on the evolving role of corticosteroids in the management of DMO. The experts: Prof. Stela Vujosevic, Medical Retina Unit, IRCCS MultiMedica and University of Milan, Milan, Italy Prof. Francesco Bandello, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy Prof. Laurent Kodjikian, University of Lyon and Croix-Rousse University Hospital, Lyon, France This touchPODCAST is for HCPs outside of the UK and USA. This activity is funded by an independent medical education grant from Alimera Sciences Europe Ltd. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchOPHTHALMOLOGY.com

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of experts in epilepsy as they discuss how to promptly and accurately diagnose and manage Lennox–Gastaut syndrome (LGS). Moderated by a leading European expert, this episode brings together faculty from the Gulf region and Japan, as they explore diagnostic approaches in their regions, before sharing their unique regional perspectives and real-world experience in caring for patients with LGS.   The experts Prof. Nicola Specchio: Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy Dr Raidah Al-Baradie: King Fahad Specialist Hospital, Dammam, Saudi Arabia Dr Taoufik Alsaadi: American Center for Neurology, Abu Dhabi, Dubai, UAE Prof. Eiji Nakagawa: National Center of Neurology and Psychiatry, Tokyo, Japan Prof. Hideo Yamanouchi: Saitama Medical University, Saitama, Japan Chapters The disease state of LGS (00:00–18:47) Managing patients with LGS in the Gulf (18:48–37:00) Managing patients with LGS in Japan (37:01–56:25) This touchPODCAST is for HCPs outside of the UK only.  This activity is supported by an independent medical educational grant from Jazz Pharmaceuticals.  Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit: touchneurologyime.org/diagnosis-treatment-lennox-gastaut-syndrome/

touchEXPERT FOCUS for touchCARDIO Listen to short interviews with two expert cardiologists discussing the role of current and emerging therapeutic classes that aim to address the unmet needs of patients with hypertrophic cardiomyopathy. The faculty will review current therapeutic approaches for managing obstructive versus nonobstructive hypertrophic cardiomyopathy to highlight existing gaps in patient care. They will then discuss the latest data for emerging therapeutic classes and consider how they may address patients’ unmet needs in the future.    The experts Dr Martin Maron, Lahey Hospital & Medical Center, Burlington, MA, USA Dr Michelle Michels, Erasmus MC, Rotterdam, The Netherlands This touchPODCAST is for healthcare professionals outside of the UK. This activity is supported by an independent medical educational grant from Cytokinetics, Inc. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:  https://touchcardio.com/

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients. Course director Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA The clinical expert Prof. Nicholas Girard, Institut Curie, Paris, France This touchPODCAST is for HCPs only. This activity is funded by an educational grant from AstraZeneca Ltd.  This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:   touchONCOLOGY: https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/ touchRESPIRATORY: https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/  

touchEXPERT FOCUS for touchONCOLOGY Listen to insights from Prof. Jean-Pascal Machiels on optimizing the use of immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and the potential future role of immunotherapy in resectable locally advanced HNSCC. The expert: Prof. Jean-Pascal Machiels, Cliniques universitaires Saint-Luc, Brussels, Belgium This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com

touchIN CONVERSATION for touchCARDIOLOGY and touchENDOCRINOLOGY Listen to two experts as they discuss the diagnosis, treatment and how to support patients with FCS. They cover how to recognize key clinical signs and symptoms, strategies to help manage symptoms, reduce triglyceride levels and prevent complications. They  also share key insights from their experience with novel targeted therapies for FCS. The expert(s) Professor Antonio Gallo, Sorbonne University Hospital Pitié-Salpêtrière, Paris, France Dr Vikesh Singh, Johns Hopkins University School of Medicine, Baltimore, MD, USA This touchPODCAST is for HCPs in the USA and Europe only. This activity is funded by an independent medical education grant from Arrowhead Pharmaceuticals, Inc. This activity is jointly provided by USF Health and touchIME.  touchIME is an EBAC® accredited provider. For further information visit our websites: https://touchcardioime.org/fcs-unmasked/ and https://touchendocrinologyime.org/fcs-unmasked/

touchEXPERT FOCUS for touchHAEMATOLOGY Prof. Lucia de Franceschi, a leading expert in sickle cell disease, examines the clinical manifestations and burden of the condition, reviews current and emerging treatments and offers guidance on comprehensive lifespan care that addresses complications, quality of life, and disparities, while highlighting the essential role of multidisciplinary support. The experts Prof. Lucia de Franceschi, University of Verona, Italy This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Agios Pharmaceuticals, Inc. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchHAEMATOLOGY.com

touchEXPERT FOCUS for touchENDOCRINOLOGY, touchCARDIO and touchNEUROLOGY Listen to a series of short expert interviews on timely diagnosis and individualized care for Fabry disease, using genetic and clinical insights. Our faculty discuss strategies to reduce diagnostic delays, identify clinically relevant genetic variants and tailor treatment based on each patient's genotype–phenotype correlations. The experts Dr Raphael Schiffmann, Texas Christian University, Fort Worth, TX, USA Ms Dawn Laney, Emory Genetic Clinical Trials Center, Atlanta, GA, USA Dr Ozlem Goker-Alpan, Lysosomal Disorders Research and Treatment Center (LDRTC), Fairfax, VA, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Amicus Therapeutics Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our websites:  www.touchENDOCRINOLOGY.com www.touchCARDIO.com and www.touchNEUROLOGY.com

touchCASES for touchONCOLOGY Listen to three experts as they discuss how patient and disease characteristics may inform treatment selection in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). They will discuss the cases of three patients which will cover first-line and second-line treatments as well as key considerations for their treatment plans in their patients' cases. The experts: Dr Nabil Saba, Winship Cancer Institute, Emory University, Atlanta, GA, USA Dr Victoria Villaflor, Chao Family Comprehensive Cancer Center, UCI Health, Orange, CA, USA This activity is for HCPs in the USA only This activity is funded by an independent medical education grant from Coherus Biosciences. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/treatment-selection-in-r-m-npc/  

touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY Listen to a series of short expert interviews on the role of B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The faculty discuss patient selection, treatment tailoring and strategies to manage side effects, providing practical guidance for integrating BCMA-targeting approaches into care. The experts Prof. Jesús San Miguel, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain Prof. Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, The Netherlands Dr Francesca Gay, University of Torino, Italy This touchPODCAST is for HCPs outside of the USA. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com